Showing 431-440 of 3810 results for "".
Managing Hot Buttons
https://practicaldermatology.com/topics/practice-management/managing-hot-buttons/18881/Host Neal Bhatia, MD sits down with Amit Garg, MD in a special one-on-one edition of Derm Insider to talk about tips for managing stress and emotional “hot buttons” in practice. They also discuss measures clinicians can take to prevent making rash decisions and better achieve their goals.Journal Club: Colloidal Oat for Prevention and Treatment
https://reachmd.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-colloidal-oat-for-prevention-and-treatment/32407/Practical Dermatology Associate Medical Editor Elizabeth (Lisa) Swanson, MD, FAAD, and Editorial Board member Lawrence Eichenfield, MD, FAAD, discuss a study demonstrating the benefits of oat for infant skincare, especially for the treatment and mitigation of atopic dermatitis.Beyond SPF: Protecting the Skin
https://practicaldermatology.com/topics/skin-cancer-photoprotection/beyond-spf-protecting-the-skin-/18535/In addition to protecting the skin from sun damage, it's becoming increasingly important to consider pollution's role in skin aging. Arianne Shadi Kourosh, MD, and Rebecca Kazin, MD discuss the need for a well tailored regimen and what to look for in sun protection, barrier protection, cleaners, anRadiesse for Hands, Alevicyn Cleared
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-radiesse-for-hands-alevicyn-cleared/18898/Merz gets FDA approval for Radiesse for hand augmentation and releases data comparing Xeomin to Botox. Heidi Waldorf, MD, FAAD and Michael Gold, MD, FAAD, comment. Also in this edition, Galderma participate in a White House forum on antibiotic stewardship, and the FDA gives 510(k) clearance to AleviLidocaine Shortage Update
https://practicaldermatology.com/conferences/scale-2023/lidocaine-shortage-update/20196/The current lidocaine and lidocaine with epinephrine shortage is affecting practices across the country. Joel L. Cohen, MD, and George Hruza, MD, weigh in on the shortage and potential solutions and how to minimize toxicity risks when mixing and matching different anesthetics.Tolerability of JAK Inhibitors Used in Dermatology
https://practicaldermatology.com/series/jak-inhibitors-in-practice/tolerability-of-jak-inhibitors-used-in-dermatology/20126/Although safety and tolerability are often intertwined, they are distinct considerations. Topical and oral JAKs used in dermatology today seem to offer good tolerability. Adelaide A. Hebert, MD and Matthew Zirwas, MD discuss potential side effects, management, and monitoring in pediatric and adult pClinical Conversations: Risks vs Benefits of JAK Inhibitors
https://practicaldermatology.com/series/jak-inhibitors-in-practice/clinical-conversations-risks-vs-benefits-of-jak-inhibitors/20108/Clinical data for JAK inhibitors show clear benefits for many patients. But these drugs are associated with certain risks and class warnings. Matt Zirwas, MD and Adelaide Hebert, MD describe how they weigh risks, educate patients, and optimize long-term management.NewDerm LIVE: Update
https://practicaldermatology.com/topics/practice-management/newderm-live-update/18844/NewDerm LIVE is coming! September 18-20, 2015 at the W Hollywood, CA. Faculty member Neal Bhatia, MD talks to program co-chairs Peter Lio, MD about the goals of the meeting, the agenda, and exciting plans for the weekend. It's not too late to be part of this one-of-a-kind event. Register nowThe Menassaince
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/the-menassaince/18722/Men are an increasingly important demographic in aesthetics today, Steven Dayan, MD tells Dermtube host Joel Cohen, MD. Unlike their female counterparts, men tend to prefer one-and-done procedures and often seek treatment after hours, he says.Why Assessing Vitiligo Activity is Critical for Limiting Spread
https://practicaldermatology.com/conferences/maui-derm-2024/why-assessing-vitiligo-activity-is-critical-for-limiting-spread/20248/Chief Medical Editor Neal Bhatia, MD talks with “Mr. Vitiligo Himself,” John E. Harris, MD, PhD about the importance of determining whether vitiligo patients are active or stable in order to “shut off” spreading as soon as possible.